Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers in patients with severe obstructive sleep apnoea: a randomised controlled trial. Issue 5 (26th October 2018)

• Record Type: Journal Article
• Authors: Recoquillon, Sylvain; Pépin, Jean-Louis; Vielle, Bruno; Andriantsitohaina, Ramaroson; Bironneau, Vanessa; Chouet-Girard, Frédérique; Fleury, Bernard; Goupil, François; Launois, Sandrine; Martinez, M Carmen; Meslier, Nicole; Nguyen, Xuan-Lan; Paris, Audrey; Priou, Pascaline; Tamisier, Renaud; Trzepizur, Wojciech; Gagnadoux, Frédéric
• Is Part Of: Thorax. Volume 74:Issue 5(2019)
• Page Start: 496
• Page End: 499
• Publication Date: 2018-10-26
• Subjects: obstructive sleep apnoea syndrome -- mandibular advancement device -- inflammation -- cytokines; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2018-212609
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein, interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide, were measured before and after 2 months of treatment with a mandibular advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the Apnoea–Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers compared with the sham device, despite high treatment adherence (6.6 hour/night). Trial registration number: NCT01426607 .